CDTX Stock Summary and Trading Ideas (Cidara Therapeutics | NASDAQ:CDTX)

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics trades on the NASDAQ stock market under the symbol CDTX.

As of April 11, 2025, CDTX stock price climbed to $18.20 with 211,926 million shares trading.

CDTX has a beta of 1.74, meaning it tends to be more sensitive to market movements. CDTX has a correlation of 0.17 to the broad based SPY ETF.

CDTX has a market cap of $199.14 million. This is considered a Micro Cap stock.

Last quarter Cidara Therapeutics reported $0 in Revenue and -$5.38 earnings per share. This fell short of revenue expectation by $-300,000 and missed earnings estimates by -$1.28.

In the last 3 years, CDTX traded as high as $42.00 and as low as $8.00.

The top ETF exchange traded funds that CDTX belongs to (by Net Assets): VTI, VXF, AVSC, IWC, PRFZ.

CDTX has outperformed the market in the last year with a return of +5.3%, while the SPY ETF gained +4.5%. However, in the most recent history, CDTX shares have underperformed the stock market with its stock returning -24.1% in the last 3 month period and -18.7% for the last 2 week period, while SPY has returned -7.7% and -3.9%, respectively.

CDTX support price is $16.05 and resistance is $18.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDTX shares will trade within this expected range on the day.